ATE180835T1 - Targeting von immunogenen durch lysosomen - Google Patents

Targeting von immunogenen durch lysosomen

Info

Publication number
ATE180835T1
ATE180835T1 AT94910648T AT94910648T ATE180835T1 AT E180835 T1 ATE180835 T1 AT E180835T1 AT 94910648 T AT94910648 T AT 94910648T AT 94910648 T AT94910648 T AT 94910648T AT E180835 T1 ATE180835 T1 AT E180835T1
Authority
AT
Austria
Prior art keywords
endosomal
lysosomal
antigens
compartment
chimeric
Prior art date
Application number
AT94910648T
Other languages
English (en)
Inventor
J Thomas August
Drew M Pardoll
Frank G Guarnieri
Original Assignee
Univ Johns Hopkins
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Johns Hopkins filed Critical Univ Johns Hopkins
Application granted granted Critical
Publication of ATE180835T1 publication Critical patent/ATE180835T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/06—Fusion polypeptide containing a localisation/targetting motif containing a lysosomal/endosomal localisation signal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/806—Antigenic peptides or proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
AT94910648T 1993-01-22 1994-01-21 Targeting von immunogenen durch lysosomen ATE180835T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/006,845 US5633234A (en) 1993-01-22 1993-01-22 Lysosomal targeting of immunogens

Publications (1)

Publication Number Publication Date
ATE180835T1 true ATE180835T1 (de) 1999-06-15

Family

ID=21722901

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94910648T ATE180835T1 (de) 1993-01-22 1994-01-21 Targeting von immunogenen durch lysosomen

Country Status (10)

Country Link
US (1) US5633234A (de)
EP (1) EP0680513B1 (de)
JP (1) JP3581366B2 (de)
AT (1) ATE180835T1 (de)
CA (1) CA2154445C (de)
DE (1) DE69418856T2 (de)
DK (1) DK0680513T3 (de)
ES (1) ES2132395T3 (de)
GR (1) GR3031026T3 (de)
WO (1) WO1994017192A2 (de)

Families Citing this family (115)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6051237A (en) † 1994-11-08 2000-04-18 The Trustees Of The University Of Pennsylvania Specific immunotherapy of cancer using a live recombinant bacterial vaccine vector
US8114414B2 (en) 1994-11-08 2012-02-14 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of cervical cancer
US7794729B2 (en) 1994-11-08 2010-09-14 The Trustees Of The University Of Pennsylvania Methods and compositions for immunotherapy of cancer
US8956621B2 (en) 1994-11-08 2015-02-17 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of cervical dysplasia
US7662396B2 (en) 2001-03-26 2010-02-16 The Trustees Of The University Of Pennsylvania Compositions and methods for enhancing the immunogenicity of antigens
US7820180B2 (en) 2004-09-24 2010-10-26 The Trustees Of The University Of Pennsylvania Listeria-based and LLO-based vaccines
US8791237B2 (en) 1994-11-08 2014-07-29 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of non-hodgkins lymphoma
DE19534170C1 (de) * 1995-09-14 1997-04-10 Univ Tuebingen Rekombinantes Polypeptid basierend auf der Primärsequenz der invarianten Kette mit mindestens einer Primärsequenz von einem spezifischen T-Zellepitop oder eines Proteinderivats und dieses rekombinante Polypeptid kodierende Nukleinsäuren
US6080409A (en) * 1995-12-28 2000-06-27 Dendreon Corporation Immunostimulatory method
US6017527A (en) * 1996-07-10 2000-01-25 Immunex Corporation Activated dendritic cells and methods for their activation
AU705647B2 (en) * 1996-07-10 1999-05-27 Immunex Corporation Method of activating dendritic cells
CA2262006A1 (en) * 1996-07-26 1998-02-05 Sloan-Kettering Institute For Cancer Research Method and reagents for genetic immunization
WO1998017323A1 (en) * 1996-10-23 1998-04-30 The Trustees Of The University Of Pennsylvania Improved vaccines
US6087174A (en) * 1996-12-26 2000-07-11 Johns Hopkins University, School Of Medicine Growth medium for primary pancreatic tumor cell culture
US7098306B2 (en) * 1997-02-13 2006-08-29 The Regents Of The University Of California Method and compositions for treating hepatocellular cancer
AU6435398A (en) * 1997-02-13 1998-09-08 University Of California, Los Angeles Prevention and treatment of hepatocellular cancer
US6054133A (en) * 1997-07-10 2000-04-25 The Regents Of The University Of California Anti-microbial targeting for intracellular pathogens
AU1801799A (en) * 1997-12-03 1999-06-28 Johns Hopkins University, The Targeting antigen-specific t cells for specific immunotherapy of autoimmune disease
US20020147143A1 (en) 1998-03-18 2002-10-10 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
EP1064390A4 (de) * 1998-03-20 2002-06-12 Genzyme Corp Gesteigerte antitumorimmunität
US7014848B1 (en) 1998-03-20 2006-03-21 Genzyme Corporation Enhanced anti-tumor immunity
ES2371432T3 (es) * 1998-05-13 2012-01-02 Epimmune Inc. Vectores de expresión para estimular una respuesta inmune y procedimientos de uso de los mismos.
WO1999058658A2 (en) * 1998-05-13 1999-11-18 Epimmune, Inc. Expression vectors for stimulating an immune response and methods of using the same
US20030235557A1 (en) 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US6667037B1 (en) * 1998-10-09 2003-12-23 Ludwig Institute For Cancer Research Isolated peptides which bind to HLA-B35 molecules, larger peptides which contain these, nucleic acid molecules encoding peptides, and uses thereof
US20040171980A1 (en) * 1998-12-18 2004-09-02 Sontra Medical, Inc. Method and apparatus for enhancement of transdermal transport
ATE312623T1 (de) * 1999-04-08 2005-12-15 Univ Johns Hopkins Antigen-spezifische induktion der peripheren immuntoleranz
US6849272B1 (en) * 1999-04-21 2005-02-01 Massachusetts Institute Of Technology Endosomolytic agents and cell delivery systems
US20050100928A1 (en) * 1999-09-16 2005-05-12 Zycos Inc., A Delaware Corporation Nucleic acids encoding polyepitope polypeptides
AU2007201619B2 (en) * 1999-09-16 2011-05-12 Eisai Inc. Nucleic acids encoding polyepitope polypeptides
US20030077263A1 (en) * 1999-10-29 2003-04-24 Immunex Corporation Method of activating dendritic cells
US7462354B2 (en) * 1999-12-28 2008-12-09 Pharmexa Inc. Method and system for optimizing minigenes and peptides encoded thereby
US20040248113A1 (en) * 1999-12-28 2004-12-09 Alessandro Sette Method and system for optimizing multi-epitope nucleic acid constructs and peptides encoded thereby
US20040002068A1 (en) 2000-03-01 2004-01-01 Corixa Corporation Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
US9012141B2 (en) 2000-03-27 2015-04-21 Advaxis, Inc. Compositions and methods comprising KLK3 of FOLH1 antigen
EP1303299B1 (de) 2000-03-29 2010-07-28 The Trustees of The University of Pennsylvania Verwendung prokariotischer pest-ähnlicher peptide zur verstärkung der immunogenität von antigenen
AU2001273149A1 (en) 2000-06-28 2002-01-08 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US8771702B2 (en) 2001-03-26 2014-07-08 The Trustees Of The University Of Pennsylvania Non-hemolytic LLO fusion proteins and methods of utilizing same
US7700344B2 (en) 2001-03-26 2010-04-20 The Trustees Of The University Of Pennsylvania Compositions and methods for enhancing the immunogenicity of antigens
EP1385538B1 (de) * 2001-04-05 2013-01-30 The Johns Hopkins University Chimäre Impfstoffe bestehend aus der Lumenal domain von LAMP-1 oder LAMP-2
CA2445577C (en) * 2001-04-30 2012-07-03 Symbiontics, Inc. Subcellular targeting of therapeutic proteins
US7629309B2 (en) * 2002-05-29 2009-12-08 Zystor Therapeutics, Inc. Targeted therapeutic proteins
US7560424B2 (en) * 2001-04-30 2009-07-14 Zystor Therapeutics, Inc. Targeted therapeutic proteins
US20040005309A1 (en) * 2002-05-29 2004-01-08 Symbiontics, Inc. Targeted therapeutic proteins
CA2446788A1 (en) 2001-05-09 2002-11-14 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US20030072761A1 (en) * 2001-10-16 2003-04-17 Lebowitz Jonathan Methods and compositions for targeting proteins across the blood brain barrier
EP2224012B1 (de) 2001-12-17 2013-01-30 Corixa Corporation Zusammensetzungen und Verfahren zur Therapie und Diagnose von entzündlicher Darmerkrankung
ATE350480T1 (de) * 2002-10-11 2007-01-15 Imvision Gmbh Moduläre antigen-transporter moleküle (mat- moleküle) zur modulierung von immunreaktionen, zugehörige konstrukte, verfahren und verwendungen
ATE465753T1 (de) * 2002-10-21 2010-05-15 Eisai Inc Zusammensetzungen und verfahren zurbehandlung von krankheiten, die durch das humane papillomavirus vermitteltwerden
WO2004048537A2 (en) * 2002-11-25 2004-06-10 Exelixis, Inc. Lamps as modifiers of the p53 pathway and methods of use
RU2389732C2 (ru) 2003-01-06 2010-05-20 Корикса Корпорейшн Некоторые аминоалкилглюкозаминидфосфатные производные и их применение
US7960522B2 (en) 2003-01-06 2011-06-14 Corixa Corporation Certain aminoalkyl glucosaminide phosphate compounds and their use
WO2004085466A2 (en) * 2003-03-28 2004-10-07 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Immunogenic hiv-1 multi-clade, multivalent constructs and methods of their use
US20050244400A1 (en) * 2004-02-10 2005-11-03 Zystor Therapeutics, Inc. Acid alpha-glucosidase and fragments thereof
JP4691495B2 (ja) * 2004-07-15 2011-06-01 一般財団法人化学及血清療法研究所 コロナウイルススパイクｓ１融合蛋白及びその発現ベクター
CA2504451A1 (en) * 2004-08-10 2006-02-10 Geron Corporation Dendritic cell vaccines for treating cancer made from embryonic stem cells
US7935804B2 (en) 2006-03-01 2011-05-03 Aduro Biotech Engineered Listeria and methods of use thereof
US20070269457A1 (en) * 2006-05-16 2007-11-22 The Buck Institute For Age Research Immunotherapeutic compositions and methods
DK2476436T3 (en) 2006-08-11 2018-02-05 Life Sciences Res Partners Vzw Immunogenic peptides and their use in immune disorders
DK2977456T3 (en) 2006-08-15 2018-01-22 Univ Pennsylvania Compositions comprising HMW-MAA and fragments thereof for the treatment of cancer
US8268326B2 (en) 2006-08-15 2012-09-18 The Trustees Of The University Of Pennsylvania Compositions comprising HMW-MAA and fragments thereof, and methods of use thereof
WO2008063511A2 (en) * 2006-11-13 2008-05-29 Zystor Therapeutics, Inc. Methods for treating pompe disease
DK2152358T3 (da) 2007-04-27 2011-06-27 Echo Therapeutics Inc Hudgennemtrængningsindretning til analytmåling og transdermal medicinafgivelse
WO2009058564A2 (en) 2007-11-01 2009-05-07 Maxygen, Inc. Immunosuppressive polypeptides and nucleic acids
AU2009214039B2 (en) 2008-02-14 2013-09-19 Katholieke Universiteit Leuven Immunogenic control of tumours and tumour cells
ES2650236T3 (es) 2008-02-14 2018-01-17 Life Sciences Research Partners Vzw Linfocitos T CD4+ con propiedades citolíticas
AU2009214038B2 (en) 2008-02-14 2013-08-22 Katholieke Universiteit Leuven Elimination of immune responses to viral vectors
CA2715611C (en) * 2008-02-14 2018-03-13 Life Sciences Research Partners Vzw Immunotherapy targeting intracellular pathogens
EP2279210B1 (de) 2008-05-07 2017-04-12 BioMarin Pharmaceutical Inc. Auf lysosomen gerichtete peptide und ihre verwendung
US9650639B2 (en) 2008-05-19 2017-05-16 Advaxis, Inc. Dual delivery system for heterologous antigens
US9017660B2 (en) 2009-11-11 2015-04-28 Advaxis, Inc. Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors
EP2288379A4 (de) 2008-05-19 2012-08-08 Advaxis Doppeltes freisetzungssystem für heterologe antigene
DK2403935T3 (en) 2009-03-04 2017-09-11 Univ Pennsylvania COMPOSITIONS CONTAINING ANGIOGENIC FACTORS AND METHODS OF USE THEREOF
WO2010124058A1 (en) 2009-04-22 2010-10-28 Indiana University Research And Technology Corporation Compositions for use in the treatment of chronic obstructive pulmonary diseases and asthma
EP2475376B1 (de) 2009-06-17 2016-03-30 BioMarin Pharmaceutical Inc. Formulierungen für lysosomale enzyme
US10016617B2 (en) 2009-11-11 2018-07-10 The Trustees Of The University Of Pennsylvania Combination immuno therapy and radiotherapy for the treatment of Her-2-positive cancers
WO2011106705A2 (en) 2010-02-26 2011-09-01 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Dna-protein vaccination protocols
ES2625406T3 (es) 2010-03-25 2017-07-19 Oregon Health & Science University Glicoproteínas de CMV y vectores recombinantes
CN107412756A (zh) 2010-10-01 2017-12-01 宾夕法尼亚大学理事会 李斯特菌疫苗载体用于在寄生虫感染的个体中扭转免疫无应答的用途
DK2643345T5 (da) 2010-11-25 2021-05-17 Imnate Sarl Immunogene peptider til anvendelse til forebyggelse og/eller behandling af infektionssygdomme, autoimmune sygdomme, immunresponser på allofaktorer, allergisygdomme, tumorer, transplantatafstødning og immunresponser på virusvektorer anvendt til genterapi eller genvaccination
EP3332804A1 (de) 2011-03-11 2018-06-13 Advaxis, Inc. Adjuvanzien auf listerien-basis
SI2691530T1 (en) 2011-06-10 2018-08-31 Oregon Health & Science University CMV glycoproteins and recombinant vectors
US20130189754A1 (en) 2011-09-12 2013-07-25 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
US9402894B2 (en) 2011-10-27 2016-08-02 International Aids Vaccine Initiative Viral particles derived from an enveloped virus
GB201201511D0 (en) 2012-01-30 2012-03-14 Univ Leuven Kath Modified epitopes for boosting CD4+ T-cell responses
EP2825195A4 (de) 2012-03-12 2015-10-07 Advaxis Inc Hemmung einer suppressorzellfunktion nach einer behandlung mit einem listerienimpfstoff
AU2012382406B2 (en) 2012-06-15 2017-12-07 Immunomic Therapeutics, Inc. Nucleic acids for treatment of allergies
EP2679596B1 (de) 2012-06-27 2017-04-12 International Aids Vaccine Initiative HIV-1 Env-proteinvariante
GB201309469D0 (en) 2013-05-28 2013-07-10 Imcyse Sa Detection of CD4+ T lymphocytes
EP2848937A1 (de) 2013-09-05 2015-03-18 International Aids Vaccine Initiative Verfahren zur Identifizierung neuartiger HIV-1-Immunogene
US10058604B2 (en) 2013-10-07 2018-08-28 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
EP3125933B1 (de) 2014-03-31 2022-05-18 Boehringer Ingelheim Vetmedica GmbH Verbesserte modulare antigentransportmoleküle und verwendung davon
GB201418433D0 (en) 2014-10-17 2014-12-03 Imcyse Sa Novel immunogenic peptides
US20170151281A1 (en) 2015-02-19 2017-06-01 Batu Biologics, Inc. Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer
US10174292B2 (en) 2015-03-20 2019-01-08 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
US9931394B2 (en) 2015-03-23 2018-04-03 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
EP3294755B1 (de) 2015-05-13 2023-08-23 The United States of America as represented by the Secretary of the Department of Health and Human Services Methoden und zusammensetzungen beruhend auf konstruktenenthaltend konservierte elemente zur induktion einer immunantwort
US10729791B2 (en) 2015-05-18 2020-08-04 Imcyse Sa Animal models for evaluating pharmaceutical compounds
US10849985B2 (en) 2015-05-20 2020-12-01 Yeda Research And Development Co. Ltd. Method of targeting senescent cells
JP7090335B2 (ja) 2015-09-25 2022-06-24 イムサイス エスエー 治療剤に対する免疫応答を除去するための改善された方法及び化合物
CA2999930A1 (en) 2015-09-30 2017-04-06 Boehringer Ingelheim Vetmedica Gmbh Improved modular antigen transportation molecules and uses therof in animals
WO2017182528A1 (en) 2016-04-19 2017-10-26 Imcyse Sa Novel immunogenic cd1d binding peptides
JP7078620B2 (ja) 2016-11-16 2022-05-31 イミュノミック セラピューティックス， インコーポレイテッド アレルギーの治療のための核酸
WO2018195527A1 (en) 2017-04-22 2018-10-25 Immunomic Therapeutics, Inc. Improved lamp constructs
CA3061950A1 (en) 2017-05-02 2018-11-08 Immunomic Therapeutics, Inc. Lamp (lysosomal associated membrane protein) constructs comprising cancer antigens
EP3424524A3 (de) * 2017-07-04 2019-02-27 CureVac AG Neuartige nukleinsäuremoleküle
KR20210007977A (ko) 2018-05-11 2021-01-20 아스텔라스세이야쿠 가부시키가이샤 진드기 알레르기 치료를 위한 핵산
KR20210007981A (ko) 2018-05-11 2021-01-20 아스텔라스세이야쿠 가부시키가이샤 갑각류 알레르기 치료를 위한 핵산
JP2021523185A (ja) 2018-05-15 2021-09-02 イミュノミック セラピューティックス， インコーポレイテッドＩｍｍｕｎｏｍｉｃ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． アレルゲンを含む改善されたｌａｍｐ構築物
MX2022002613A (es) 2019-09-03 2022-06-02 Myeloid Therapeutics Inc Metodos y composiciones para la integracion del genoma.
US20240108703A1 (en) 2019-10-18 2024-04-04 Immunomic Therapeutics, Inc. Improved LAMP Constructs Comprising Cancer Antigens
IL293718A (en) * 2019-12-11 2022-08-01 Myeloid Therapeutics Inc Therapeutic cell preparations and methods for their production and use
AU2021376354A1 (en) 2020-11-04 2023-06-22 Myeloid Therapeutics, Inc. Engineered chimeric fusion protein compositions and methods of use thereof
WO2022197949A2 (en) 2021-03-17 2022-09-22 Myeloid Therapeutics, Inc. Engineered chimeric fusion protein compositions and methods of use thereof
WO2023201201A1 (en) 2022-04-10 2023-10-19 Immunomic Therapeutics, Inc. Bicistronic lamp constructs comprising immune response enhancing genes and methods of use thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4237115A (en) * 1977-11-23 1980-12-02 Bactex, Inc. Method of immunization against enterotoxogenic infection by Escherichia coli
US4397844A (en) * 1978-02-24 1983-08-09 Ciba-Geigy Corporation Antigen derivatives and processes for their preparation
GB2026340B (en) * 1978-07-03 1982-12-22 Ash P Stabilising microvesicles
US4406885A (en) * 1978-12-28 1983-09-27 Research Corporation Preparation of native oncornavirus envelope subunits and vaccines therefrom
EP0031812B1 (de) * 1979-03-27 1983-06-15 National Research Development Corporation Verbesserungen an immunologischen zusammensetzungen
US4681762A (en) * 1979-05-23 1987-07-21 Research Corporation Genetically attenuated bacterial vaccines with multiple mutations of the same phenotype
US4769330A (en) * 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US4593002A (en) * 1982-01-11 1986-06-03 Salk Institute Biotechnology/Industrial Associates, Inc. Viruses with recombinant surface proteins
US4578458A (en) * 1983-03-23 1986-03-25 Brigham And Women's Hospital Mucoid exopolysaccharide vaccine against Pseudomonas aeruginosa
US4738846A (en) * 1984-08-30 1988-04-19 The Salk Institute For Biological Studies Vaccine for vesicular stomatitis virus
ZA858044B (en) * 1984-11-01 1987-05-27 American Home Prod Oral vaccines
US5260422A (en) * 1988-06-23 1993-11-09 Anergen, Inc. MHC conjugates useful in ameliorating autoimmunity
AU2752892A (en) * 1991-09-26 1993-04-27 Oklahoma Medical Research Foundation Fusion proteins targeted to lysosomes, for the treatment of aids

Also Published As

Publication number Publication date
CA2154445A1 (en) 1994-08-04
ES2132395T3 (es) 1999-08-16
US5633234A (en) 1997-05-27
CA2154445C (en) 2007-06-26
EP0680513B1 (de) 1999-06-02
DE69418856D1 (de) 1999-07-08
WO1994017192A2 (en) 1994-08-04
JPH08505878A (ja) 1996-06-25
WO1994017192A3 (en) 1994-09-15
GR3031026T3 (en) 1999-12-31
EP0680513A1 (de) 1995-11-08
DE69418856T2 (de) 2000-01-20
DK0680513T3 (da) 1999-12-27
JP3581366B2 (ja) 2004-10-27

Similar Documents

Publication Publication Date Title
ATE180835T1 (de) Targeting von immunogenen durch lysosomen
Zeng et al. Self-adjuvanting nanoemulsion targeting dendritic cell receptor Clec9A enables antigen-specific immunotherapy
WO2002080851A3 (en) Chimeric vaccines
DE50209178D1 (de) Moduläre Antigen-Transporter Moleküle (MAT-Moleküle) zur Modulierung von Immunreaktionen, zugehörige Konstrukte, Verfahren und Verwendungen
EP1363660A4 (de) "überlegene molekulare vakzine auf basis selbstreplizierender rna, suizid-dna oder nacktem dna-vektor, zur verknüpfung von antigen mit polypeptid zur förderung der antigenpräsentation"
RU2017138373A (ru) Праймирование иммунного ответа
EP1798239A3 (de) G-Protein-gekoppelte Rezeptoren und deren Verwendung
LV12085A (lv) Dendritiskas sunas stimulejosais faktors
Colluru et al. B lymphocytes as direct antigen-presenting cells for anti-tumor DNA vaccines
WO2006065821A8 (en) Improved dna immunization with recombinase/transposase
MX2023010640A (es) Péptidos neoantigénicos transmembranales.
Muthumani et al. Co‐immunization with an optimized plasmid‐encoded immune stimulatory interleukin, high‐mobility group box 1 protein, results in enhanced interferon‐γ secretion by antigen‐specific CD8 T cells
WO2003066820A3 (en) Nucleic acid molecules encoding cd1-derived endosomal targeting proteins and uses thereof
Nagata et al. Immunization with plasmid DNA encoding MHC class II binding peptide/CLIP-replaced invariant chain (Ii) induces specific helper T cells in vivo: the assessment of Ii p31 and p41 isoforms as vehicles for immunization
Yi et al. Improved efficacy of DNA vaccination against breast cancer by boosting with the repeat beta-hCG C-terminal peptide carried by mycobacterial heat-shock protein HSP65
Mukai et al. HER2 peptide-specific CD8+ T cells are proportionally detectable long after multiple DNA vaccinations
NZ500151A (en) A general method for attaching DNA molecule comprising non-antibody target molecule (eg. CTLA-4 or L-selectin), antigen or epitope sequence, and optionally a polypeptide sequence
CN102657854A (zh) 多表位疫苗yl66以及在制备肿瘤治疗性疫苗中的应用
Chowdhury et al. Generation of high titer antisera in rabbits by DNA immunization
Bråve et al. Late administration of plasmid DNA by intradermal electroporation efficiently boosts DNA-primed T and B cell responses to carcinoembryonic antigen
ATE395422T1 (de) Chimäre antikörper zur abgabe von antigenen an selektierte zellen des immunsystems
Neal et al. Hydrodynamic limb vein delivery of a xenogeneic DNA cancer vaccine effectively induces antitumor immunity
DE60130634D1 (de) Identifizierung von antigenen peptiden durch zytotoxische t-lymphozyten aktiviert von dendritischen zellhybriden
Cafri et al. Development of novel genetic cancer vaccines based on membrane‐attached β2 microglobulin
Johansson et al. Intracellular targeting of CEA results in Th1‐type antibody responses following intradermal genetic vaccination by a needle‐free jet injection device

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification